Comparisons of efficacy and complications between transrectal and transperineal prostate biopsy with or without antibiotic prophylaxis

•TPBx significantly reduced infectious complications compared with TRBx and should therefore be preferred•We need to re-examine whether the antibiotic prophylaxis should be routinely applied before TPBx in consideration of increasing antibiotic resistance•Future studies on this topic with improved q...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Urologic oncology 2022-05, Vol.40 (5), p.191.e9-191.e14
Hauptverfasser: He, Junwei, Guo, Zhenlang, Huang, Yanqin, Wang, Zhaohui, Huang, Lijuan, Li, Baimou, Bai, Zunguang, Wang, Shusheng, Xiang, Songtao, Gu, Chiming, Pan, Jun
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•TPBx significantly reduced infectious complications compared with TRBx and should therefore be preferred•We need to re-examine whether the antibiotic prophylaxis should be routinely applied before TPBx in consideration of increasing antibiotic resistance•Future studies on this topic with improved quality and increased sample size are still needed to minimise bacterial resistance We aimed to determine the cancer detection rate and complications of transrectal prostate biopsy (TRBx) and transperineal prostate biopsy (TPBx) in the hospital. However, given the use of antibiotic prophylaxis in TPBx remains controversial according to the current guidelines, we also investigated the safety and side effects of TPBx with and without antibiotic prophylaxis. A total of 777 patients who underwent prostate biopsy were enrolled in this study in accordance with the criteria. The primary outcome was pooled infectious complications (sepsis, fever, symptomatic urinary tract infection and urinary retention), and the secondary outcome was prostate cancer detection rate. Findings showed that TPBx and TRBx were equivalent in terms of prostate cancer detection rate (TPBx: 50.4% vs. TRBx: 47.3%; P = 0.424) and urinary retention (TPBx: 5% vs. TRBx: 6.3%; P = 0.451). However, TRBx had significantly higher incidences of sepsis (risk ratios, RR: 3.65, 95% confidence interval [CI]: 1.21–11.03; P = 0.014) and symptomatic urinary tract infection (RR: 3.04, 95% CI: 1.07–8.66; P = 0.029) than TPBx. Notably, for TPBx, patients who received a single dose of cephazolin prophylaxis were not associated with the risk of sepsis (RR: 0.78, 95% CI: 0.13–4.63; P = 0.783) and symptomatic urinary tract infection (RR: 1.17, 95% CI: 0.24–5.74; P = 0.848) in contrast to patients who did not receive any antibiotic prophylaxis. Meanwhile, no effects on prostate cancer detection rate and urinary retention were observed in the TPBx group. Our findings indicated that TPBx significantly reduced infectious complications compared with TRBx and should therefore be preferred. Importantly, we need to re-examine whether the antibiotic prophylaxis should be routinely applied before TPBx in consideration of increasing antibiotic resistance. This result complements the current national guidelines. Nevertheless, future studies on this topic with improved quality and increased sample size are still needed to minimise bacterial resistance.
ISSN:1078-1439
1873-2496
1873-2496
DOI:10.1016/j.urolonc.2022.01.004